CD274 and breast cancer: However, this mechanism is expected to rather result into a negative impact of tumorcellular PD-L1 expression on survival, and this is reported, e.g. for breast cancer, NSCLC, renal cell carcinoma (for meta-analysis see [26]), osteosarcoma, [27] or advanced melanoma.